HDL Proteome in Hemodialysis Patients: A Quantitative Nanoflow Liquid Chromatography-Tandem Mass Spectrometry Approach

Alain Mangé1,2,3,*, Aurélie Goux2,5,*, Stéphanie Badiou2,4,5, Laure Patriert2,4,5, Bernard Canaud2,5,6, Thierry Maudelonde1,2,3, Jean-Paul Cristol2,4,5, Jérôme Solassol1,2,3,*

1 CHU Arnaud de Villeneuve, Dept of Cellular Biology, Montpellier, France, 2 University of Montpellier I, Montpellier, France, 3 Val d’Aurelle Cancer Institute, Dept of Clinical Oncoproteomic, Montpellier, France, 4 CHU Lapeyronie, Dept of Biochemistry, Montpellier, France, 5 UMR 204 NUTRIPASS (University of Montpellier I/II), Montpellier, France, 6 CHU Lapeyronie, Dept of Nephrology, Montpellier, France

Abstract
Aside from a decrease in the high-density lipoprotein (HDL) cholesterol levels, qualitative abnormalities of HDL can contribute to an increase in cardiovascular (CV) risk in end-stage renal disease (ESRD) patients undergoing chronic hemodialysis (HD). Dysfunctional HDL leads to an alteration of reverse cholesterol transport and the antioxidant and anti-inflammatory properties of HDL. In this study, a quantitative proteomics approach, based on iTRAQ labeling and nanoflow liquid chromatography mass spectrometry analysis, was used to generate detailed data on HDL-associated proteins. The HDL composition was compared between seven chronic HD patients and a pool of seven healthy controls. To confirm the proteomics results, specific biochemical assays were then performed in triplicate in the 14 samples as well as 46 sex-matched independent chronic HD patients and healthy volunteers. Of the 122 proteins identified in the HDL fraction, 40 were differentially expressed between the healthy volunteers and the HD patients. These proteins are involved in many HDL functions, including lipid metabolism, the acute inflammatory response, complement activation, the regulation of lipoprotein oxidation, and metal cation homeostasis. Among the identified proteins, apolipoprotein C-II and apolipoprotein C-III were significantly increased in the HDL fraction of HD patients whereas serum transferrin was decreased. In this study, we identified new markers of potential relevance to the pathways linked to HDL dysfunction in HD. Proteomic analysis of the HDL fraction provides an efficient method to identify new and uncharacterized candidate biomarkers of CV risk in HD patients.

Introduction
In the general population, a decrease in high-density lipoprotein (HDL) cholesterol levels, qualitative abnormalities of HDL can contribute to an increase in cardiovascular (CV) risk in end-stage renal disease (ESRD) patients undergoing chronic hemodialysis (HD). Dysfunctional HDL leads to an alteration of reverse cholesterol transport and the antioxidant and anti-inflammatory properties of HDL. In this study, a quantitative proteomics approach, based on iTRAQ labeling and nanoflow liquid chromatography mass spectrometry analysis, was used to generate detailed data on HDL-associated proteins. The HDL composition was compared between seven chronic HD patients and a pool of seven healthy controls. To confirm the proteomics results, specific biochemical assays were then performed in triplicate in the 14 samples as well as 46 sex-matched independent chronic HD patients and healthy volunteers. Of the 122 proteins identified in the HDL fraction, 40 were differentially expressed between the healthy volunteers and the HD patients. These proteins are involved in many HDL functions, including lipid metabolism, the acute inflammatory response, complement activation, the regulation of lipoprotein oxidation, and metal cation homeostasis. Among the identified proteins, apolipoprotein C-II and apolipoprotein C-III were significantly increased in the HDL fraction of HD patients whereas serum transferrin was decreased. In this study, we identified new markers of potential relevance to the pathways linked to HDL dysfunction in HD. Proteomic analysis of the HDL fraction provides an efficient method to identify new and uncharacterized candidate biomarkers of CV risk in HD patients.

Citation: Mangé A, Goux A, Badiou S, Patriert L, Canaud B, et al. (2012) HDL Proteome in Hemodialysis Patients: A Quantitative Nanoflow Liquid Chromatography-Tandem Mass Spectrometry Approach. PLoS ONE 7(3): e34107. doi:10.1371/journal.pone.0034107

Copyright: © 2012 Mangé et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: The authors have no support or funding to report.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: jerome.solassol@univ-montp1.fr

These authors contributed equally to this work.

atherosclerosis [8–12]. CV diseases are recognized as the major cause of mortality and morbidity in HD patients [15–16]. Lipid disorders in HD patients are mainly related to ESRD-induced alterations in lipoprotein metabolism, especially the accumulation of very-low-density lipoproteins (VLDL), a shift in the LDL subclass and alterations in HDL maturation [12,17]. Patients usually display elevated triglycerides, unchanged or even reduced LDL cholesterol, and decreased HDL cholesterol [13,14]. In addition, the HD procedure itself can worsen the lipid profile by further decreasing the HDL cholesterol and increasing the LDL cholesterol levels after a session [18]. Aside from a decrease in HDL cholesterol, the CV risk in HD patients is also enhanced by the qualitative abnormalities that lead to dysfunctional HDL [19–22].

Because the HDL proteome is involved in HDL functionality, we applied a quantitative proteomics approach to investigate the proteins associated with HDL in HD patients and healthy subjects. We used 8-plex iTRAQ reagents and 2D nanoflow liquid chromatography-mass spectrometry analysis (2D nano-LC/MS/MS) to identify the qualitative and quantitative differences in the proteins purified from the HDL fractions between the HD patients.
and healthy volunteers. We aimed to identify proteins with a potential relevance in lipid metabolism and the oxidative and inflammatory pathways that could be linked to the HDL dysfunction in HD patients. The identification of new relevant markers could further be used to evaluate the CV risk related to the abnormal HDL proteome.

Materials and Methods

Ethics statement
The patients were recruited from the Department of Nephrology using protocols approved by the institutional review board of the University Hospital of Montpellier. Informed consent was obtained from all patients.

Patient selection
Seven chronic HD patients on renal replacement therapy and seven healthy volunteers were included in the discovery study population. The validation study population consisted of 23 additional sex-matched HD patients and 23 healthy volunteers. The validation study population was sex-matched but not age-matched. The absence of age-matching in the validation study population should be considered a limitation. All HD patients received online hemodiafiltration treatments three times per week, with ultra-pure boricarbonate-based dialysate using a high flux polysulphone membrane (HF-80, Fresenius). Three patients received ivabradine, and 13 patients received statins (Table S1). Blood samples were collected on the arterial line before the mid-week dialysis session. All the healthy volunteers were blood donors for the French Blood Agency. Individuals exhibiting acute or chronic infection, hypertension, or diabetes and those requiring medications were excluded. Blood sampling was performed during the blood donation. The plasma was obtained using EDTA-coated tubes, by centrifugation at 3,000 rpm for 15 min, and was stored at −80°C before analysis. All samples were collected during the same month and were subjected to the same number of freeze/thaw cycles (n = 2, before HDL isolation and before proteomic or biochemical analysis).

Human plasma HDL isolation
The HDL fraction (d = 1.063–1.21 g/ml) from each sample was isolated from the plasma by sequential density ultracentrifugation in three steps using potassium bromide (KBr), as previously described by Morena et al. [22]. Briefly, the VLDL and LDL were sequentially removed by ultracentrifugation at 70,000 rpm for 4 h at 4°C after the adjustment of the plasma density to 1.019 and 1.063 g/ml with KBr, respectively. The HDL fraction was obtained by adjusting the infranatant density to 1.21 g/ml with KBr prior to ultracentrifugation. The HDL fraction was dialyzed against PBS for 24 h at 4°C. Aliquots of the HDL samples were stored at −80°C. The protein concentration was measured in triplicate using the Micro BCA Kit (Pierce). The purity of the HDL fraction was assessed through the measurement of the apolipoprotein (apo) A-I and apoB levels by immunonephelometric assay (Immage 800, Beckman). All samples exhibited an apoB level under the limit of detection (i.e. <0.35 g/L) and an apoA-I level from 1.50 to 5.70 g/L (Table S1).

Biochemical analyses
The quantification of the total cholesterol, HDL cholesterol, and triglycerides in the plasma and in the HDL fraction was determined using routine assays on the chemistry analyzer Architect C8000 (Abbott). In the HDL fraction, the phospholipid concentration was determined on the same analyzer using reagent from the Diasys Diagnostic System. The quantification of serotransferrin (reagent from Beckman), apoC-II and apoC-III (reagent from Randox), in the HDL fraction, was performed by immunoturbidimetric assay on an AU640 analyzer (Beckman). Haptoglobin, in the HDL fraction, was measured using the AssayMax Haptoglobin ELISA kit (AssayPro). All assays were performed in triplicate. The mean individual data are shown in Table S1.

iTRAQ reagent labeling and peptide processing
The experimental design used for this study is illustrated in Figure S1. A pool of seven healthy volunteers was used as a reference “control sample”, against which all of the HD patients were compared. By pooling the healthy samples, the potential loss of statistical power arising from a reduced sample size is offset by the reduction in the standard error of the means. iTRAQ labeling was performed according to the manufacturer’s protocol (AB Sciex). Briefly, 50 μg of proteins from the HDL control pool and from the seven HD patients was precipitated using four volumes of acetone. The pelleted proteins were dissolved into 500 mM triethylammonium bicarbonate/1% SDS. The proteins were reduced with 5 mM tris-(2-carboxyethyl) phosphine, alkylated with 10 mM methyl methane-thiosulfonate, and trypsin digested overnight. The resulting peptides were labeled for two hours with one of the eight isobaric amine-reactive tags (Figure S1). The labeled peptides were combined and cleaned up using a strong cation exchange cartridge, according to the manufacturer’s recommended protocol (AB Sciex). The strong cation exchange eluents were desalted using an Oasis HLB extraction cartridge (Waters Corporation) and vacuum dried before IEF separation.

The peptides were separated using the Agilent 3100 OFFGEL Fractionator (Agilent). Briefly, an IPG Drystrip (24 cm, pH 3–10) was rehydrated for 15 min with 20 μl/well of a solution containing 0.25% IPG buffer, pH 3–10 (GE Healthcare). The desalted peptides were dissolved in the 0.25% IPG buffer, pH 3–10, and the peptide solution (150 μl) was pipetted into each well. Twenty-four well fractionations were focused for 50 kVh, with a maximum current of 50 μA and power of 200 mW. The fractions were purified using OMIX C18 100 μl pipette tips (Varian). The peptides were eluted and lyophilized before being reconstituted for the 2D nano-LC/MS/MS analysis.

Mass spectrometry analysis of the protein extracts
The peptides were separated using an Ultimate 3000 nano-LC system coupled to a Probot™ Microfraction Collector ( Dionex). The nano-LC separations were performed using an Acclaim PepMap™ (C18, 3 μm, 100 A/75 μm/15 cm column. The mobile phases used were 2% acetonitrile (ACN) with 0.05% trifluoroacetic acid (TFA) (A) and 80% ACN with 0.05% TFA (B). The gradient elution steps were performed with a flow rate of 0.3 μl/min as follows: 0–50% B over 60 min, 50–80% B over 30 min, 80–100% B over 5 min, and then 100% B for an additional 10 min. The fractions were mixed directly with the matrix-assisted laser desorption/ionization (MALDI) matrix solution (2 mg/ml α-cyano-4-hydroxycinnamic acid in 70% ACN with 0.1% TFA) at a flow rate of 1.2 μl/min. Forty fmol of human [Glu1] Fibrinopeptide B (m/z 1570.57) was spiked into each spot as an internal standard. Spotting onto the Opti-TOF™ LC/MALDI insert plates (AB Sciex) was performed using the Probot spotting device over a 110-min period at a speed of 11 s per well.

The plates were analyzed using a MALDI time of flight (MALDI TOF/TOF) 4800 mass spectrometer (AB Sciex). MS spectra from m/z 700 to 4000 were acquired in positive reflector ion mode using 750 laser shots. The ten most abundant peptide
under the reporter peaks, from the control samples (m/z 95% probability of being correct. The use of a reversed-decoy database from the same UniProt database was considered positively identified. The estimated local FDR of 5%) were considered positively identified. The unused protein score, calculated by ProteinPilot, is a protein threshold of 1.3 (which corresponds to a confidence score of 95%).

**Data analysis and interpretation**

The protein identification and quantification were performed with the ProteinPilot™ Software 2.0.1 (AB Scie). The MS/MS spectra obtained were searched against the UniProt database (UniProtKB release 2009_09). The search parameters for trypic cleavage and accuracy are built-in functions of the software. The other data analysis parameters were as follows: 8-plex iTRAQ peptide labeling, cys-alkylation by MMTS, biological modifications, a thorough identification search, and a minimum detected protein threshold of 1.3 (which corresponds to a confidence score of 95%). The unused protein score, calculated by ProteinPilot, is a measurement of the confidence in the protein identification after taking into account all of the peptide data for a given protein and excluding any evidence that is better explained by a higher ranking protein. Proteins comprising one or more peptides with a high confidence score (>95%) and a low false discovery rate (FDR) (estimated local FDR of 5%) were considered positively identified. A reversed-decoy database from the same UniProt database was used to estimate the local FDR using the Proteomics System Performance Evaluation Pipeline (PSPEP) tool [23]. The use of a 5% local FDR indicates that each protein identified has at least a 95% probability of being correct.

The relative quantification was based on the ratio of the areas under the reporter peaks, from the control samples (m/z 113 Da) and the patient samples (m/z 114, 115, 116, 117, 118, 119, and 121 Da). The following criteria were required to select a protein for further analysis: two or more unique peptides with a high confidence score (>95%), a p-value for protein quantification <0.05, greater than a 1.3-fold difference relative to the control sample, and detection of the protein in more than 50% of the HD patient samples (at least 4 of the 7 HD patient samples). For more information about the quantification methodology, see the Text S1.

**Statistical analysis**

The results are expressed as the mean ± standard error of the mean (SEM). The statistical analyses were performed using the Mann-Whitney U test using GraphPad InStat. A p-value of <0.05 was chosen for statistical significance. The enrichment analysis of the gene ontology (GO) was determined using the DAVID bioinformatics resources [24]. The significance of the gene-term enrichment was determined using a modified Fisher’s exact test (EASE score), which ranks the overrepresented GO processes.

**Results**

**Proteomic HDL analysis of the discovery population**

The characteristics of the patients, for both study populations, are summarized in Table 1 and Table S1. In the discovery and in the validation set, the HD patients exhibited significantly lower cholesterol levels than the healthy subjects, including lower HDL cholesterol and lower LDL cholesterol levels. There was no difference in the plasma triglyceride levels between the HD and healthy subjects, in either the discovery or the validation set.

Using iTRAQ labeling and 2D nano-LC/MS/MS, a total of 303 non-redundant proteins were identified and quantified for the comparison between the seven individual HD patients and the seven healthy volunteers. Among these proteins, 122 were further selected using stringent criteria, such as containing one or more peptides with a >95% confidence score and a 5% local FDR. The complete MS and MS/MS data are shown in Table S2 and Table S3.

The iTRAQ peptide labeling efficiency was 98.8%. Only 40 of the 122 proteins showed a differential expression in the HD patients that also corresponded to our selection criteria (identified and quantified in at least four of the seven HD patients, a differential expression of at least 1.3-fold relative to the control samples, and a p-value <0.05). The complete list of the proteins defined by these criteria and confidently identified, containing at least two peptides with a high confidence score, is shown in Table 2. Among the 40 selected proteins, more than 68% were found to be differentially expressed in at least six of the HD patients (10 were upregulated and 17 were downregulated) compared with the healthy subjects.

The biological processes and the molecular functions of all of the proteins identified in the HDL fraction were classified using a GO classification system and are presented in Table S4. The

---

**Table 1. Clinical characteristics of the study population.**

|                   | Discovery set Healthy n = 7 | Discovery set HD n = 7 | p-value* | Validation set Healthy n = 23 | Validation set HD n = 23 | p-value* |
|-------------------|-----------------------------|------------------------|----------|-------------------------------|--------------------------|----------|
| **Gender**        | 3M/4F                       | 3M/4F                  | NS       | 15M/8F                       | 15M/8F                   | NS       |
| **Age (years)**   | 59.7 ± 0.36                 | 69.1 ± 3.59            | NS       | 56.6 ± 0.76                  | 69.7 ± 3.01              | <0.05    |
| **Plasma (mmol/L, mean ± SEM)** |                      |                        |          |                              |                          |
| Total cholesterol | 5.4 ± 0.44                  | 3.7 ± 0.38             | <0.05    | 5.0 ± 0.23                   | 3.7 ± 0.21               | <0.05    |
| Triglyceride      | 1.5 ± 0.25                  | 1.5 ± 0.37             | NS       | 1.3 ± 0.11                   | 1.5 ± 0.19               | NS       |
| HDL-Cholesterol   | 1.2 ± 0.13                  | 1.1 ± 0.23             | <0.05    | 1.4 ± 0.07                   | 1.0 ± 0.07               | <0.05    |
| LDL-Cholesterol   | 3.0 ± 0.35                  | 1.8 ± 0.24             | <0.05    | 2.9 ± 0.20                   | 1.9 ± 0.13               | <0.05    |
| **HDL (mmol/L, mean ± SEM)** |                      |                        |          |                              |                          |
| Total cholesterol | 4.8 ± 0.41                  | 5.4 ± 1.01             | NS       | 4.7 ± 0.43                   | 5.2 ± 0.40               | NS       |
| Triglyceride      | 0.4 ± 0.05                  | 0.5 ± 0.09             | NS       | 0.4 ± 0.05                   | 0.7 ± 0.13               | <0.05    |
| Phospholipids     | 3.7 ± 0.22                  | 4.5 ± 0.56             | NS       | 3.7 ± 0.29                   | 4.5 ± 0.32               | <0.05    |
| Total lipids      | 8.9 ± 0.60                  | 10.4 ± 1.58            | NS       | 8.8 ± 0.75                   | 10.5 ± 0.75              | NS       |

*Mann-Whitney test.
doi:10.1371/journal.pone.0034107.t001

---
proteins were associated with a broad range of molecular functions such as lipid and cholesterol transport, lipid metabolism, inflammatory response, the complement and coagulation cascade, the response to metal ions, hemostasis, and endopeptidase inhibitory activity. We investigated the enrichment of the 40 differentially expressed proteins using the functional classification tool. Table 3 shows the GO categories associated with the 40 differentially expressed proteins. Individual mapping of the upregulated and downregulated proteins shows that the lipid/cholesterol transport and metabolism proteins were the most significant functional processes represented by the upregulated proteins, whereas the acute inflammatory response, complement activation, and endo-

| Uniprot accession n’ | Gene symbol | Protein name | HD 1 | HD 2 | HD 3 | HD 4 | HD 5 | HD 6 | HD 7 |
|----------------------|-------------|--------------|------|------|------|------|------|------|------|
| **Upregulated**      |             |              |      |      |      |      |      |      |      |
| P02652               | APOA2       | Apolipoprotein A-II | 1.86 | 3.31 | 2.86 | 1.34 | 2.57 | 2.45 | 2.30 |
| P02656               | APOC3       | Apolipoprotein C-III | 3.24 | 3.11 | 2.65 | 2.84 | 3.65 | 3.70 | 1.94 |
| P02760               | AMBP        | Protein AMBP | 1.41 | 1.97 | 1.58 | 1.85 | 1.94 | 1.91 | 1.42 |
| P03090               | APOD        | Apolipoprotein D | 1.51 | 1.41 | 1.30 | 1.56 | 1.72 | 1.63 | 1.49 |
| P02655               | APOC2       | Apolipoprotein C-II | 2.64 | 2.97 | 2.87 | 3.00 | 4.42 | 4.43 | 2.11 |
| P35542               | SAA4        | Serum amyloid A-4 protein | 1.99 | 2.35 | 1.54 | 1.53 | 1.52 | 2.76 | 1.80 |
| P08519               | LPA         | Apolipoprotein(α) | 2.81 | 1.60 | 1.43 | 2.83 | 1.14 | 2.81 | 1.79 |
| P02753               | RBP4        | Retinol-binding protein 4 | 1.80 | 2.18 | 1.25 | 1.96 | 1.45 | 1.60 | 1.59 |
| P02654               | APOC1       | Apolipoprotein C-I | 1.37 | 1.79 | 2.05 | 1.54 | 1.96 | 2.49 | 1.84 |
| P04180               | LCAT        | Phosphatidylcholine-sterol acyltransferase | 2.46 | 1.72 | 1.57 | 1.39 | 1.54 | 1.74 | 1.33 |
| P06727               | APOA4       | Apolipoprotein A-IV | 1.12 | 2.05 | 1.39 | 2.55 | 1.20 | 1.71 | 1.54 |
| P02649               | APOE        | Apolipoprotein E | 1.01 | 1.49 | 1.09 | 2.94 | 1.26 | 2.62 | 1.81 |
| P02735               | SAA1        | Serum amyloid A protein | 1.42 | 1.32 | 1.32 | 0.80 | 8.90 | 3.43 | 0.96 |
| O95445               | APOM        | Apolipoprotein M | 1.66 | 1.44 | 1.28 | 1.58 | 1.31 | 1.40 | 1.14 |
| P27169               | PON1        | Serum paraoxonase/arylesterase 1 | 2.32 | 1.47 | 0.97 | 1.56 | 1.98 | 1.10 | 1.60 |
| P55056               | APOC4       | Apolipoprotein C-IV | 1.35 | 2.16 | 1.30 | 1.99 | 2.27 | 2.88 | 0.83 |
| Q14791               | APOL1       | Apolipoprotein L1 | 1.78 | 2.00 | 1.19 | 0.91 | 1.31 | 1.33 | 1.02 |
| P04114               | APOB        | Apolipoprotein B-100 | 1.41 | 1.39 | 1.10 | 1.21 | 1.98 | 1.56 | 1.10 |
| P61769               | B2M         | Beta-2-microglobulin | 2.14 | 3.68 | 3.73 | 2.12 | 3.69 | 3.74 | 3.29 |
| **Downregulated**    |             |              |      |      |      |      |      |      |      |
| P02787               | TF          | Serotransferrin | 0.36 | 0.36 | 0.43 | 0.57 | 0.32 | 0.43 | 0.48 |
| P01024               | C3          | Complement C3 | 0.65 | 0.54 | 0.65 | 0.71 | 0.55 | 0.64 | 0.58 |
| P02675               | FGB         | Fibrinogen beta chain | 0.47 | 0.50 | 0.39 | 0.51 | 0.33 | 0.36 | 0.38 |
| P00738               | HP          | Haptoglobin | 0.39 | 0.27 | 0.33 | 0.44 | 0.37 | 0.32 | 0.47 |
| P01876               | IGHA1       | Ig alpha-1 chain C region | 0.34 | 0.33 | 0.32 | 0.62 | 0.36 | 0.36 | 0.41 |
| P01023               | A2M         | Alpha-2-macroglobulin | 0.24 | 0.19 | 0.25 | 0.25 | 0.20 | 0.24 | 0.22 |
| P02679               | FGG         | Fibrinogen gamma chain | 0.58 | 0.37 | 0.33 | 0.54 | 0.35 | 0.39 | 0.39 |
| P08603               | CFH         | Complement factor H | 0.47 | 0.32 | 0.48 | 0.64 | 0.37 | 0.42 | 0.48 |
| P01842               | IGLC1       | Ig lambda chain C regions | 0.45 | 0.37 | 0.59 | 0.60 | 0.35 | 0.36 | 0.53 |
| P01871               | IGHM        | Ig mu chain C region | 0.45 | 0.22 | 0.30 | 0.50 | 0.28 | 0.26 | 0.33 |
| P02751               | FN1         | Fibrinectin | 0.44 | 0.34 | 0.34 | 0.57 | 0.32 | 0.29 | 0.36 |
| P02671               | FGA         | Fibrinogen alpha chain | 0.49 | 1.02 | 0.55 | 0.69 | 0.40 | 0.44 | 0.50 |
| P02790               | HPX         | Hemopexin | 0.46 | 0.46 | 0.53 | 0.81 | 0.47 | 0.68 | 0.64 |
| P01042               | KNG1        | Kininogen-1 | 0.57 | 0.71 | 0.75 | 0.92 | 0.43 | 0.77 | 0.66 |
| P00734               | F2          | Prothrombin | 0.47 | 0.46 | 0.56 | 0.70 | 0.52 | 0.77 | 0.73 |
| P04196               | HRG         | Histidine-rich glycoprotein | 0.38 | 0.53 | 0.49 | 0.88 | 0.37 | 0.53 | 0.58 |
| Q14624               | ITH4        | Inter-alpha-trypsin inhibitor heavy chain H4 | 0.69 | 0.39 | 0.55 | 0.60 | 0.35 | 0.58 | 0.58 |
| P04004               | VTN         | Vitronectin | 0.60 | 0.61 | 0.54 | 0.71 | 0.48 | 0.66 | 0.65 |
| P01008               | SERPINC1    | Antithrombin-III | 0.64 | 0.68 | 0.85 | 1.00 | 0.67 | 0.73 | 0.82 |
| P10909               | CLU         | Clusterin | 0.67 | 0.58 | 0.77 | 1.09 | 0.62 | 0.93 | 0.86 |
| P01700               | LV102       | Ig lambda chain V-l region HA | 0.42 | 0.45 | 0.40 | 0.49 | 0.21 | 0.25 | 0.38 |

Ratios of at least 1.3-fold relative to the control samples, and a p-value<0.05 are indicated in bold.

doi:10.1371/journal.pone.0034107.t002
peptidase inhibitor activity were the most significant functional processes represented by the downregulated proteins.

**Confirmation of the differential levels of HDL-associated proteins in the discovery study population by biochemical analysis**

A panel of four proteins identified by MS analysis in all seven HD patients (two upregulated [apoC-II and apoC-III] and two downregulated [serotransferrin and haptoglobin]) was selected to confirm the changes in the protein expression that was observed in the proteomic analysis. These four proteins were quantified in the same population using biochemical or immunological assays. The results were in agreement with the MS findings, and we showed a significant correlation between the iTRAQ and the biochemical quantification ratio for the four proteins (Table 4). There were no significant differences between the iTRAQ and the biochemical quantification ratios, except for apoC-II and serotransferrin (Table 4). The comparison of the iTRAQ reporter ion signal intensities revealed a 3.11-fold increase and a 0.41-fold decrease in apoC-II and serotransferrin, respectively, in the HD patients as compared with the control pool. These results are consistent with the 6.53-fold increase and 0.14-fold decrease, respectively, detected by the biochemical quantification using the same samples, even if the magnitude of observed change is far greater than that seen in the iTRAQ assay ($p$-value $<0.05$ and $p$-value $<0.005$ for apoC-II and serotransferrin, respectively). When we compared the expression of each protein, the expression of apoC-II and apoC-III were significantly higher in the HDL fraction of the HD patients when compared with the healthy volunteers whereas serotransferrin and haptoglobin showed significantly lower expression in the HDL fraction of the HD patients when compared with the healthy volunteers (Figure 1A).

**Differential levels of the HDL-associated proteins in an independent validation study population**

We quantified apoC-II, apoC-III, serotransferrin and haptoglobin in the HDL fraction of 23 additional healthy control volunteers and 23 sex-matched HD patients (Table 5 and Figure 1B). The apoC-II in the HDL fraction was confirmed to be significantly higher in the HD patients (11.4 mg/mg of protein, Table 3. The gene ontology category enrichments for the differentially expressed proteins in the HDL fraction.

| Gene Ontology Category                                      | P-value* | iTRAQ expression | Gene symbol |
|-------------------------------------------------------------|----------|------------------|-------------|
| Acute inflammatory response (GO:0002526)                    | 4.00E-11 | Down-regulated   | FN1, TF, KNG1, ITIH4, CFH, CLU, C3, A2M, F2 |
| Endopeptidase inhibitor activity (GO:0004866)               | 9.00E-07 | Down-regulated   | HRG, KNG1, ITIH4, SERPINC1, C3, A2M |
| Heparin binding (GO:0008201)                                | 2.10E-06 | Down-regulated   | HRG, FN1, SERPINC1, VTN |
| Complement and coagulation cascade (KEGG hsa04610)          | 3.30E-14 | Down-regulated   | FGG, FGA, KNG1, FGB, SERPINC1, CFH, C3, A2M, F2 |
| Cation homeostasis (GO:0005080)                             | 3.80E-04 | Down-regulated   | TF, KNG1, HP, HPX, F2 |
| Lipid transport (GO:0006869)                                | 5.00E-26 | Up-regulated     | RBP4, APOB, APOA4, LCAT, LPA, APOL1, APOE, APOC2, APOC3, APOM, APOA2, APOC4, APOC1 |
| Cholesterol transport (GO:00030301)                         | 2.70E-19 | Up-regulated     | APOB, APOA4, LCAT, APOE, APOC2, APOC3, APOM, APOA2, APOC1 |
| Cholesterol metabolic process (GO:0008203)                  | 2.40E-13 | Up-regulated     | APOB, APOA4, LCAT, APOL1, APOE, APOC3, APOA2, APOC1 |
| Lipid metabolic process (GO:00019216)                       | 1.20E-12 | Up-regulated     | APOB, APOA4, APOE, APOC2, APOC3, APOM, APOA2, APOC1 |
| Regulation of lipoprotein oxidation (GO:0003442)            | 5.60E-06 | Up-regulated     | PON1, APOA4, APOM |

*Enrichment P-values were calculated using a modified Fischer’s exact test (EASE score).

doi:10.1371/journal.pone.0034107.t003

**Table 4. Comparison of the iTRAQ ion ratios and the biochemical quantification ratios.**

| Protein name          | Ratio | HD 1 | HD 2 | HD 3 | HD 4 | HD 5 | HD 6 | HD 7 | Mean | Correlation | Pearson r | p-value |
|-----------------------|-------|------|------|------|------|------|------|------|------|-------------|-----------|---------|
| Apolipoprotein C-II   |       |      |      |      |      |      |      |      |      |             |           |         |
| iTRAQ                 | 2.64  | 2.97 | 2.87 | 3    | 4.42 | 4.43 | 2.11 | 3.11 | 0.89 | 0.008        |           |         |
| Quant                 | 5.12  | 5.3  | 3.66 | 8.89 | 9.53 | 11.51| 1.71 | 6.53 |     |             |           |         |
| Apolipoprotein C-III  |       |      |      |      |      |      |      |      |      |             |           |         |
| iTRAQ                 | 3.24  | 3.11 | 2.65 | 2.84 | 3.65 | 3.7  | 1.94 | 2.96 | 0.85 | 0.03         |           |         |
| Quant                 | 1.38  | 3.54 | 2.23 | 3.02 | 3.11 | 3.8  | 2.03 | 2.73 |     |             |           |         |
| Serotransferrin       |       |      |      |      |      |      |      |      |      |             |           |         |
| iTRAQ                 | 0.36  | 0.36 | 0.43 | 0.57 | 0.32 | 0.43 | 0.48 | 0.41 | 0.90 | 0.006        |           |         |
| Quant                 | 0     | 0    | 0.05 | 0.56 | 0    | 0.2  | 0.13 | 0.14 |     |             |           |         |
| Haptoglobin           |       |      |      |      |      |      |      |      |      |             |           |         |
| iTRAQ                 | 0.39  | 0.27 | 0.33 | 0.43 | 0.37 | 0.32 | 0.47 | 0.36 | 0.89 | 0.02         |           |         |
| Quant                 | 0.22  | 0.14 | 0.29 | 0.48 | 0.62 | 0.27 | 0.59 | 0.33 |     |             |           |         |

doi:10.1371/journal.pone.0034107.t004
95% CI [8.1–14.8]), when compared with the healthy controls (3.1 μg/mg of protein, 95% CI [2.0–4.2]). A similar result was obtained with apoC-III, which was found to be significantly higher in the HD patients (22.5 μg/mg of protein, 95% CI [17.4–27.6]) when compared with the healthy controls (7.5 μg/mg of protein, 95% CI [6.1–8.9]). Therefore, the apoC-II/apoC-III ratio was also found to be significantly higher in the HD patients (ratio of 0.42) when compared with the healthy controls (ratio of 0.25). The serotransferrin levels in the HDL fraction were significantly lower in the HD patients (6.7 μg/mg of protein, 95% CI [4.5–8.9]) when compared with the healthy controls (16.4 μg/mg of protein, 95% CI [13.1–19.7]). In contrast, there were no confirmed differences in the haptoglobin levels between the healthy controls and the HD patients (9.5 μg/mg of protein, 95% CI [5.4–14.2]). Neither age nor the lipid-lowering drugs taken by some patients were shown to have a significant impact on our validation data (Table 5).

**Discussion**

In this study, we investigated the HDL proteome in HD patients who are considered to have a high risk for CV diseases. Multidimensional nano-LC/MS/MS was used for the analysis of the HDL samples, which were labeled with isobaric mass tags (iTRAQ) to identify the proteins that were differentially expressed between the HDL fractions of the HD patients and the healthy volunteers. Earlier studies have identified approximately 50 distinct proteins associated with the HDL fraction, using 2D electrophoresis and mass spectrometry approaches [19,25–29]. Notably, in our 2D nano-LC/MS/MS approach, we greatly improved the HDL fraction proteome coverage by identifying 122 proteins associated with the HDL fraction, including 80–90% of the previously identified proteins [19,25–30]. The proteins associated with HDL have been implicated in a wide range of functions, such as lipid metabolism, inflammatory response, the complement and coagulation cascade, and the activity of the endopeptidase inhibitor. Among the proteins involved in lipoprotein metabolism, we detected several apolipoproteins and enzymes that are already known to be associated with HDL, such as apoA-I, apoA-II, apoA-IV, apoC-II, apoC-III, apoC-IV, apoD, apoE, apoJ, apoL-I, apoM, lecithin cholesterol acyl transferase, and the cholesterol ester transfer protein. In addition, we identified other proteins associated with the HDL fraction that are related to the inflammation and oxidative pathways, such as the serum amyloid proteins, paraoxonase-1 and 3, α1-antitrypsin, and several complement component proteins.

We identified 40 differentially expressed proteins, with a high confidence score, between the HD patients and the healthy volunteer samples; of these proteins, four proteins that were differentially expressed in all seven HD patients and that were previously shown to be associated with HDL [28,31] were used to validate the proteomic analysis. The validation step confirmed the increase of apoC-II and apoC-III in the HDL fraction of HD patients compared with the healthy controls. Both apoC-II and apoC-III were elevated in the HDL fraction of the HD patients, leading to an increase in the apoC-II/apoC-III ratio. This observation is surprising when considering the respective functions.

Figure 1. The expression analysis of apoC-II, apoC-III, serotransferrin and haptoglobin in the HDL fractions of the healthy volunteers and the HD patients. The concentration of the proteins in the 14 samples of the discovery set (A) and in the 46 samples of the validation set (B) were determined using biochemical analyses. The mean is indicated by the horizontal line.
doi:10.1371/journal.pone.0034107.g001

HDL-Associated Proteins in Hemodialysis
of apoC-II and apoC-III, which are to activate and inhibit lipoprotein lipase activity, respectively [32]. VLDL accumulation related to impaired lipoprotein lipase activity and a decrease in the plasma apoC-II/apoC-III ratio are classically observed in HD patients [12]. Nevertheless, the increase of both apoC-II and apoC-III in the HDL fraction of the HD patients does not predict the activity of lipoprotein lipase for VLDL delipidation, because the active form of apoC-II or apoC-III are carried by VLDL [33]. It can be hypothesized that the increase of apoC-II and apoC-III in the HDL fraction could be a marker of impaired maturation of the HDL particles, leading not only to dysfunctional HDL, but also to an overall alteration of lipoprotein metabolism through modification in the exchange of apoC. Recent studies have demonstrated that an increase in the plasma apoC-II levels was positively associated with the smaller sizes of the HDL particles, and this association was even higher when the elevation of apoC-II and apoC-III occurred simultaneously [34]. Another study, performed on HD patients, demonstrated a relationship between a change in the HDL proteome, including an increase of apoC-III, and a change in the in vitro HDL functionality, as assessed by their ability to promote cholesterol efflux in lipid-laden macrophages [19]. Oxidative stress and inflammatory, which are frequently observed in HD patients, could contribute to the formation of dysfunctional HDL, as suggested by in vitro studies [35,36]. Finally, concordant to our study, dysfunctional HDL and the impairment of reverse cholesterol transport have been shown to be key features of dyslipidemia in HD and have been shown to contribute to the high risk for CV diseases [12,19–22].

The atheroprotective effects of HDL are mediated, aside from the reverse cholesterol transport function, by the antioxidative and anti-inflammatory properties of HDL [2,4,5]. For example, HDL may prevent LDL oxidation, a key event in the initiation and progression of vascular atherosclerotic lesions [3]. Interestingly, impairment of the HDL antioxidant properties in HD patients was previously demonstrated using an in vitro LDL oxidation model [21,22]. Among the processes involved in LDL oxidation, metal cations, such as iron or copper, may promote the initial step of lipid peroxidation [37]. Our study identified a cluster of proteins involved in metal cation homeostasis, such as haptoglobin and serotransferrin, for which the expression was decreased in the HDL fraction of the HD patients compared with the healthy volunteers. In agreement with the previous data shown in plasma [38], the haptoglobin levels in the HDL fraction of the HD patients appear downregulated when compared with the controls in our discovery study population. Haptoglobin, an acute phase protein, avidly binds to hemoglobin that is released into the plasma during physiological and pathological hemolysis and prevents the iron- and heme-mediated oxidative side effects [39,40]. Unfortunately, the validation step in our independent

### Table 5. The differential expression levels of apoC-II, apoC-III, serotransferrin and haptoglobin in the independent healthy and HD validation study population.

|                | Healthy | HD | p-value* |
|----------------|---------|----|----------|
|                | N       | Concentration (µg/mg of protein) | N       | Concentration (µg/mg of protein) |          |
| Apolipoprotein C-II | 23 | 3.1, 95% CI [2.0–4.2] | 23 | 11.4, 95% CI [8.1–14.8] | <0.0001   |
| Age >56a | 8 | 3.0, 95% CI [1.2–4.8] | 6 | 8.2, 95% CI [3.1–13.3] | <0.05     |
| No Treatment | - | 3.1, 95% CI [2.0–4.2] | 11 | 9.8, 95% CI [4.6–15.1] | <0.05     |
| With Treatment | - | 3.1, 95% CI [2.0–4.2] | 12 | 13.2, 95% CI [8.3–18.1] | <0.0001   |
| Apolipoprotein C-III | 23 | 7.5, 95% CI [6.1–8.9] | 23 | 22.5, 95% CI [17.4–27.6] | <0.0001   |
| Age >56a | 8 | 6.3, 95% CI [3.4–9.3] | 6 | 20.5, 95% CI [11.8–29.1] | <0.05     |
| No Treatment | - | 8.1, 95% CI [6.5–9.8] | 17 | 23.2, 95% CI [16.6–29.9] | <0.05     |
| With Treatment | - | 7.5, 95% CI [6.1–8.9] | 11 | 20.7, 95% CI [13.3–28.0] | <0.001    |
| Serotransferrin | 23 | 16.4, 95% CI [13.1–19.7] | 23 | 6.7, 95% CI [4.5–8.9] | <0.0001   |
| Age >56a | 8 | 17.8, 95% CI [12.8–22.7] | 6 | 8.0, 95% CI [3.1–13.0] | <0.05     |
| No Treatment | - | 15.6, 95% CI [10.9–20.3] | 17 | 6.2, 95% CI [3.5–8.9] | <0.001    |
| With Treatment | - | 16.4, 95% CI [13.1–19.7] | 11 | 6.9, 95% CI [4.1–9.9] | <0.001    |
| Haptoglobin | 23 | 9.5, 95% CI [5.2–13.8] | 23 | 9.8, 95% CI [5.4–14.2] | NS        |
| Age >56a | 8 | 10.3, 95% CI [1.9–16.4] | 6 | 9.0, 95% CI [1.5–16.4] | NS        |
| No Treatment | - | 9.0, 95% CI [3.2–14.7] | 17 | 10.0, 95% CI [4.2–16.0] | NS        |
| With Treatment | - | 9.5, 95% CI [5.2–13.8] | 11 | 6.6, 95% CI [2.2–10.9] | NS        |

* Mann-Whitney test.
* Healthy and HD patient groups were divided into patients under the age of 56 and patients above the age of 56.
* HD patient group was divided into patients treated with lipid-lowering drugs and patients without treatment, and each HD subgroup was compared with the healthy patient group.

doi:10.1371/journal.pone.0034107.t005

PLoS ONE | www.plosone.org 7 March 2012 | Volume 7 | Issue 3 | e34107
study population did not confirm the significant difference between the groups. However, the haptoglobin levels should be interpreted with caution in the HD patients, since many conditions such as hemolysis, folate deficiency, liver disease, anemia, infection or inflammation can lead to haptoglobin variations. These confounding factors could explain the dissociation observed for the haptoglobin levels between the discovery and the validation study populations. Serotransferrin, the major iron binding protein, transports iron between the sites of absorption, storage, and utilization and delivers the iron required for cellular processes [41]. Interestingly, serotransferrin has already been shown to be associated with HDL, using both western blot and proteomic analyses [28,42]. Notably, the in vitro oxidation of LDL by copper was inhibited by HDL containing serotransferrin and ceruloplasmin. In contrast, the removal of the lipoproteins containing serotransferrin or ceruloplasmin reduced the ability of the lipoproteins to inhibit the oxidation of LDL [42]. Therefore, it could be hypothesized that the decrease of serotransferrin in the HDL fraction of the HD patients leads to decreased protection against LDL oxidation.

In conclusion, we showed that HD patients exhibit major modifications of their HDL proteome, in addition to the quantitative decrease of HDL cholesterol. When comparing a fixed amount of HDL-associated proteins, 40 proteins, primarily involved in lipid metabolism, the inflammation pathway, complement activation, and metal cation homeostasis, appear to be differentially expressed between the HD patients and the healthy volunteers. The expression level of apolH-I, apolH-III, and serotransferrin was validated in an independent population set, improving the reliability of our findings. Note that chronic HD is a complex therapy, and the comparison of the HDL proteome between patients undergoing HD and healthy subjects does not allow us to distinguish the effects of ESRD and HD itself. Although further investigations with a larger number of subjects will be needed to determine whether the proteins identified in this study can be used as relevant CV-risk biomarkers, we identified proteins with a potential relevance to the pathways linked to HDL dysfunction in chronic HD patients.

Supporting Information

Figure S1 Experimental design. (TIF)

Table S1 Clinical characteristics of the study population. (XLS)

Table S2 Protein summary report generated by ProteinPilot. (XLS)

Table S3 Peptide summary report generated by ProteinPilot. (XLS)

Table S4 Enriched biological process and molecular function using the gene ontology classification (http://david.abcc.ncifcrf.gov). (XLS)

Text S1 (DOC)

Author Contributions

Conceived and designed the experiments: AM AG SB JPC TM JS. Performed the experiments: AM AG SB. Analyzed the data: AM AG SB JPC JS. Contributed reagents/materials/analysis tools: LP BC. Wrote the paper: AM AG SB JS.

References

1. Ansell BJ, Navarro M, Hama S, Kamranpour N, Fonarow G, et al. (2003) Inflammatory/antinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment. Circulation 108: 2751–2756.
2. Kontush A, Chapman MJ (2006) Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidaemia, inflammation, and atherosclerosis. Pharmacol Rev 58: 342–374.
3. Watson AD, Berliner JA, Hama SY, La Du BN, Faull KF, et al. (1995) Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. J Clin Invest 96: 2012–2019.
4. Feig JE, Shamir R, Fisher EA (2008) Atheroprotective effects of HDL beyond reverse cholesterol transport.Curr Drug Targets 9: 196–203.
5. Ansell BJ, Fonarow GC, Fogelman AM (2007) The paradox of dysfunctional high-density lipoprotein. Curr Opin Lipidol 18: 427–434.
6. Yu R, Yekta B, Vakili L, Gharavi N, Navab M, et al. (2008) Proatherogenic high-density lipoprotein, vascular inflammation, and mimetic peptides. Curr Atheroscler Rep 10: 171–176.
7. G HB, Rao VS, Kalkar VV (2011) Friend Turns Foe: Transformation of Anti-Inflammatory HDL to Proinflammatory HDL during Acute-Phase Response. Cholesterol 2011: 274629.
8. Morena M, DiBosco S, Dupay AM, Cauda B, Cristol JP (2005) Overproduction of reactive oxygen species in end-stage renal disease patients: a potential component of hemodialysis-associated inflammation. Hemodial Int 9: 37–46.
9. Nguyen AT, Leithas C, Zingraff J, Herbelin A, Naret C, et al. (1985) Hemodialysis membrane-induced activation of phagocyte oxidative metabolites detected in vivo and in vitro within microamounts of whole blood. Kidney Int 28: 156–167.
10. Peachant E, Carboneau MA, DuBourg I, Thomas MJ, Perromat A, et al. (1994) Liperoxidation in plasma and red blood cells of patients undergoing haemodialysis: vitamin A, E, and iron status. Free Radic Biol Med 16: 339–346.
11. Stenvinkel P, Alvestrand A (2002) Inflammation in end-stage renal disease: sources, consequences, and therapy. Semin Dial 15: 329–337.
12. Vaziri ND (2006) Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences. Am J Physiol Renal Physiol 290: F262–272.
13. Attman PO, Alapovac P (1993) Lipid and apolipoprotein profiles of uremic lipoproteinemia—relation to renal function and dialysis. Nephron 57: 401–410.
14. Sutherland WH, Garey J, Walker RJ, Robertson MC, Ball MJ (1995) Cell cholesterol transport to plasma in blood from patients with renal failure or a kidney transplant. Nephrol Dial Transplant 10: 358–365.
15. Go AS, Chertow GM, Fan D, McCullough CE, Hsu CY (2004) Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351: 1296–1305.
16. Muntner P, He J, Astor BC, Folsom AR, Coresh J (2005) Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: results from the atherosclerosis risk in communities study. J Am Soc Nephrol 16: 529–538.
17. Deignahan CJ, Calsakke MJ, McConnell M, Boulton-Jones JM, Packard CJ (2000) Atherogenic lipoprotein phenotype in end-stage renal failure: origin and extent of small dense low-density lipoprotein formation. Am J Kidney Dis 35: 852–862.
18. Montauroirr F, Hashemi M, Karajbanab M, Dikshit M (2010) Hemodialysis alters lipid profiles, total antioxidant capacity, and vitamins A, E, and C concentrations in humans. J Med Food 13: 1490–1493.
19. Holzer M, Birner-Gruenberger R, Stejakovic T, ElGamal D, Binder V, et al. (2011) Uremia alters HDL composition and function. J Am Soc Nephrol 22: 1611–1614.
20. Jurak A, Turyna B, Kubík P, Klein A (2008) The ability of HDL to inhibit VCAM-1 expression and oxidized LDL uptake is impaired in renal patients. Clin Biochem 41: 1015–1018.
21. Moradi H, Pahl MV, Elshinehur R, Vaziri ND (2009) Impaired antioxidant activity of high-density lipoprotein in chronic kidney disease. Transl Res 153: 77–85.
22. Morena M, Cristol JP, Dantoine T, Carbonneau MA, Descomps B, et al. (2000) Protective effects of high-density lipoprotein against oxidative stress are impaired in haemodialysis patients. Nephrol Dial Transplant 15: 389–395.
23. Tang WH, Shihov IV, Seymour SI (2008) Nonlinear fitting method for determining local false discovery rates from decoy database searches. J Proteome Res 7: 3663–3667.
24. Dennis G, Jr., Sherman BT, Hosack DA, Yang J, Gao W, et al. (2005) DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol 4: P3.
25. Davidson WS, Silva RA, Chantepie S, Lagor WR, Chapman MJ, et al. (2009) Proteomic analysis of defined HDL subpopulations reveals particle-specific protein clusters: relevance to antioxidative function. Arterioscler Thromb Vasc Biol 29: 870–876.
26. Gordon SM, Deng J, Lu LJ, Davidson WS (2010) Proteomic Characterization of Human Plasma High Density Lipoprotein Fractionated by Gel Filtration Chromatography. J Proteome Res 9: 5239–5249.

27. Karlsson H, Leonardson P, Tegesson C, Lindeahl M (2005) Lipoproteomics II: mapping of proteins in high-density lipoprotein using two-dimensional gel electrophoresis and mass spectrometry. Proteomics 5: 1431–1445.

28. Rezaee F, Caserta B, Level JK, Speijer D, Meijers JC (2006) Proteomic analysis of high-density lipoprotein. Proteomics 6: 721–730.

29. Vainar T, Pennathur S, Green PS, Gharib SA, Hoofnagle AN, et al. (2007) Shotgun proteomics implicates protease inhibition and complement activation in the anti-inflammatory properties of HDL. J Clin Invest 117: 746–756.

30. Davidson P, Hulthe J, Fagerberg B, Camejo G (2010) Proteomics of apolipoproteins and associated proteins from plasma high-density lipoproteins. Arterioscler Thromb Vasc Biol 30: 156–163.

31. Hoofnagle AN, Heinecke JW (2009) Lipoproteomics: using mass spectrometry-based proteomics to explore the assembly, structure, and function of lipoproteins. J Lipid Res 50: 1967–1975.

32. Jong MC, Hofker MH, Havekes LM (1999) Role of ApoCs in lipoprotein metabolism: functional differences between ApoC1, ApoC2, and ApoC3. Arterioscler Thromb Vasc Biol 19: 472–484.

33. Bakberg PR, Le NA, Gimberg KN, Gibson JC, Rubinstein A, et al. (1985) Evidence for non-equilibrating pools of apolipoprotein C-III in plasma lipoproteins. J Lipid Res 26: 1047–1057.

34. Tian L, Wu J, Fu M, Xu Y, Jin L (2000) Relationship between apolipoprotein C-III concentrations and high-density lipoprotein subclass distribution. Metabolism 50: 660–674.

35. Shao B, Oda MN, Oram JF, Heinecke JW (2006) Myeloperoxidase: an inflammatory enzyme for generating dysfunctional high density lipoprotein. Curr Opin Cardiol 21: 322–328.

36. McGillicuddy FC, de la Llera Moya M, Hinkle CC, Joshi MR, Chiquoine EH, et al. (2009) Inflammation impairs reverse cholesterol transport in vivo. Circulation 119: 1135–1145.

37. Blokhina O, Virolainen E, Fagerstedt KV (2003) Antioxidants, oxidative damage and oxygen deprivation stress: a review. Ann Bot 91 Spec No: 179–194.

38. Weinstein T, Chagnac A, Korzets A, Boaz M, Ori Y, et al. (2000) Haemolysis in haemodialysis patients: evidence for impaired defence mechanisms against oxidative stress. Nephrol Dial Transplant 15: 883–887.

39. Katoh N, Nakagawa H (1999) Detection of haptoglobin in the high-density lipoprotein and the very high-density lipoprotein fractions from sera of calves with experimental pneumonia and cows with naturally occurring fatty liver. J Vet Med Sci 61: 119–124.

40. Nielsen MJ, Petersen SV, Jacobsen C, Oxvig C, Rees D, et al. (2006) Haptoglobin-related protein is a high-affinity hemoglobin-binding plasma protein. Blood 108: 2846–2849.

41. Chua AC, Graham RM, Trinder D, Olynyk JK (2007) The regulation of cellular iron metabolism. Crit Rev Clin Lab Sci 44: 413–459.

42. Kunitake ST, Jarvis MR, Hamilton RL, Kane JP (1992) Binding of transition metals by apolipoprotein A-I-containing plasma lipoproteins: inhibition of oxidation of low density lipoproteins. Proc Natl Acad Sci U S A 89: 6993–6997.